Selpercatinib Approved for Metastatic MTC

In September, we were delighted to hear that the National Institute for Clinical Excellence (NICE) had approved the targeted kinase inhibitor, selpercatinib, for use in thyroid cancers, including medullary thyroid cancer (MTC), that have spread due to a change in the RET gene (in people over 12 years old). Selpercatinib is more specific than other tyrosine kinase inhibitors (e.g. cabozanitinib) at targeting the RET gene meaning that it usually has far fewer side effects. MTC can occur alone (sporadic) or as part of MEN types 2 and 3, and has often already spread upon diagnosis. Selpercatinib is now available via the Cancer Drugs Fund in England.

The Scottish Medicine’s Consortium (SMC) also approved selpercatinib in September, on an interim basis in Scotland for people over 12 years old. AMEND was thankful to be able to provide a full patient group submission to the SMC process, thanks to the help of the MTC community and the wonderful support received from the SMC itself.

We are hugely thankful to AMEND member, Kirstie Purnell and our MTC patient volunteer (who wishes to remain anonymous), who were of enormous help in providing patient input into both processes.

More Information from NICE

More Information from SMC